Results 181 to 190 of about 676,531 (303)

Colon‐Targeted Berberine Nanoparticles‐Embedded Yeast Microcapsules for Regulation of Gut Immunity of Sepsis

open access: yeseFood, Volume 7, Issue 4, August 2026.
A schematic representation illustrating the preparation of BGNP@YM and its therapeutic effects on septic mice induced by lipopolysaccharide (LPS). (A) BBR is first encapsulated within GNPs to form BGNPs with anti‐inflammatory activity, which are subsequently coated with YM via chemical precipitation to obtain the BGNP@YM oral delivery system.
Qing‐Qing Dong   +6 more
wiley   +1 more source

Gut microbiota‐targeted interventions for depression in adolescents and young adults: Mechanisms, evidence strength and clinical strategies—A narrative review

open access: yesGeneral Psychiatry, Volume 39, Issue 4, August 2026.
ABSTRACT Depression in adolescents and young adults is common, associated with substantial functional impairment and characterised by limited treatment efficacy. The microbiota–gut–brain (MGB) axis has emerged as a potential therapeutic target for depression.
Hanchen Hou   +15 more
wiley   +1 more source

Disrupted endocannabinoid signaling contributes to systemic inflammation in acute pancreatitis

open access: yesThe Journal of Pathology, Volume 269, Issue 4-5, Page 462-477, August 2026.
Abstract Acute pancreatitis (AP) is an inflammatory disease that can lead to systemic complications in severe cases. The endocannabinoid system has emerged as a potential modulator of inflammation in AP. We investigated the role of the endocannabinoid 2‐arachidonoylglycerol (2‐AG) and the cannabinoid receptors CB1 and CB2 during AP.
Paula Goncalves‐Romeu   +7 more
wiley   +1 more source

Differentiation of Novel Human .ALPHA.-Amylase from Salivary and Pancreatic .ALPHA.-Amylases.

open access: yesJournal of the Japanese Society of Starch Science, 1991
OMICHI, Kaoru   +3 more
openaire   +2 more sources

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote   +10 more
wiley   +1 more source

Clinical Implications and Research Progress of Salivary Biomarkers for Endocrine and Metabolic Disorders

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6561-6575, August 2026.
ABSTRACT Aims Similar to blood, saliva contains a broad range of biomarkers and may offer a non‐invasive, repeatable specimen for endocrine and metabolic assessment. This review aims to synthesise and evaluate recent advances in the clinical translation of salivary biomarkers, while providing a critical assessment of the diagnostic reliability and ...
Chuyan Yu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy